病例系列：疥疮并发杜匹单抗治疗特应性皮炎。

IF 1.8 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2025-08-30 DOI:10.1111/ajd.14589

Madeleine Louise Kelly, Robert M Miller

{"title":"病例系列：疥疮并发杜匹单抗治疗特应性皮炎。","authors":"Madeleine Louise Kelly, Robert M Miller","doi":"10.1111/ajd.14589","DOIUrl":null,"url":null,"abstract":"We present a case series of four patients who had scabies diagnosed while on Dupilumab treatment for atopic dermatitis. The Type 2 immune response is the primary immune response for both ordinary and crusted scabies, and Dupilumab inhibits this response. This inhibition could be the reason behind treatment resistance and crusted presentations in this case series. Clinicians should be aware of the possible development of scabies in patients on Dupilumab and the potential of scabies masquerading as atopic dermatitis at the time of instituting this medication.","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case Series: Scabies Complicating Dupilumab Therapy for Atopic Dermatitis.\",\"authors\":\"Madeleine Louise Kelly, Robert M Miller\",\"doi\":\"10.1111/ajd.14589\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We present a case series of four patients who had scabies diagnosed while on Dupilumab treatment for atopic dermatitis. The Type 2 immune response is the primary immune response for both ordinary and crusted scabies, and Dupilumab inhibits this response. This inhibition could be the reason behind treatment resistance and crusted presentations in this case series. Clinicians should be aware of the possible development of scabies in patients on Dupilumab and the potential of scabies masquerading as atopic dermatitis at the time of instituting this medication.\",\"PeriodicalId\":8638,\"journal\":{\"name\":\"Australasian Journal of Dermatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australasian Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajd.14589\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajd.14589","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们提出了一个病例系列的四名患者谁有疥疮诊断而杜匹单抗治疗特应性皮炎。2型免疫反应是普通疥疮和结痂疥疮的主要免疫反应，Dupilumab抑制这种反应。这种抑制可能是本病例系列中治疗耐药和结痂的原因。临床医生应该意识到在使用杜匹单抗的患者中可能出现疥疮，以及在使用这种药物时疥疮伪装成特应性皮炎的可能性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Case Series: Scabies Complicating Dupilumab Therapy for Atopic Dermatitis.

We present a case series of four patients who had scabies diagnosed while on Dupilumab treatment for atopic dermatitis. The Type 2 immune response is the primary immune response for both ordinary and crusted scabies, and Dupilumab inhibits this response. This inhibition could be the reason behind treatment resistance and crusted presentations in this case series. Clinicians should be aware of the possible development of scabies in patients on Dupilumab and the potential of scabies masquerading as atopic dermatitis at the time of instituting this medication.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.